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Introduction: There is an urgent need for health authorities across Europe to fully realize
potential savings from increased use of generics to sustain their healthcare systems. A
variety of strategies were used across Europe following the availability of generic losartan,
the first angiotensin receptor blocker (ARB) to be approved and marketed, to enhance its
prescribing vs. single-sourced drugs in the class. Demand-side strategies ranged from
100% co-payment for single-sourced ARBs in Denmark to no specific measures. We
hypothesized this heterogeneity of approaches would provide opportunities to explore
prescribing in a class following patent expiry.
Objective: Contrast the impact of the different approaches among European countries
and regions to the availability of generic losartan to provide future guidance.
Methodology: Retrospective segmented regression analyses applying linear random
coefficient models with country specific intercepts and slopes were used to assess the
impact of the various initiatives across Europe following the availability of generic losartan.
Utilization measured in defined daily doses (DDDs). Price reductions for generic losartan
were also measured.
Results: Utilization of losartan was over 90% of all ARBs in Denmark by the study
end. Multiple measures in Sweden and one English primary care group also appreciably
enhanced losartan utilization. Losartan utilization actually fell in some countries with no
specific demand-side measures. Considerable differences were seen in the prices of
generic losartan.
Conclusion: Delisting single-sourced ARBs produced the greatest increase in losartan
utilization. Overall, multiple demand-side measures are needed to change physician
prescribing habits to fully realize savings from generics. There is no apparent “spill over”
effect from one class to another to influence future prescribing patterns even if these are
closely related.
Keywords: losartan, generics, demand-side measures, cross-national study, drug utilisation, Europe
INTRODUCTION
Health authorities across Europe could realize considerable sav-
ings through greater use of generic medicines. Between 2008 and
2013, the global annual sales of medicines losing their exclusivity
was US$50 to 100 billion (C35–70 billion), reaching US$255 bil-
lion by 2016 (Frank, 2007; Jack, 2008; Godman et al., 2014).
Once one or more drugs in a class lose their patent, and all
drugs in the class are seen as essentially therapeutically similar at
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appropriate doses, it is legitimate for health authorities to encour-
age physicians to preferentially prescribe low cost generics to
realize considerable savings without compromising care (Voncina
et al., 2011; Godman et al., 2014). However, physicians and
authorities do not always take full advantage of the availability of
generics (Godman et al., 2010a, 2014). The availability of generic
losartan provides an exemplar case to review health authority
activities across Europe and the subsequent implications.
Renin-angiotensin inhibitor drugs had global sales of US$27.3
billion in 2010, 24% in Europe, much of this for single-sourced
angiotensin receptor blockers (ARBs) (IMS Institute for Health
Informatics, 2011). Broadly speaking, all angiotensin converting
enzyme inhibitors (ACEIs) and ARBs are seen as having simi-
lar effectiveness for the management of hypertension and heart
failure at appropriate dose titration (Heran et al., 2008; Moon
et al., 2010; Voncina et al., 2011; Bucsics et al., 2012; Svanstrom
et al., 2012; Godman et al., 2013a; Simoens et al., 2013). Patients
in the UK have also been successfully switched between differ-
ent ARBs without compromising care (Usher-Smith et al., 2008;
Moon et al., 2010). However, other authors disagree believing
losartan is inferior to other ARBs (Makani et al., 2014).
A variety of strategies were instigated by national and regional
health authorities across Europe to preferentially encourage the
prescribing of losartan once generic losartan became available.
These included 100% co-payment for single-sourced ARBs in
Denmark unless there was a good medical rationale, which effec-
tively de-listed single-sourced ARBs (Hesse et al., 2013). Other
strategies including removing prescribing restrictions for losartan
but not for single-sourced ARBs, instigating prescribing targets
for losartan vs. single-sourced ARBs, physician financial incen-
tive schemes and therapeutic switching programmes (Bucsics
et al., 2012; Godman et al., 2013a; Simoens et al., 2013; Martin
et al., 2014). However, some authorities did nothing (Bennie
et al., 2013; Godman et al., 2013b). We hypothesized this het-
erogeneity of approaches offers the opportunity for a “natural
experiment” of prescribing in a class following patent expiry, and
to benchmark the effectiveness and financial utility of different
interventions to provide insight for future opportunities.
Consequently, the aim of the study is to compare and con-
trast the impact of the many different demand-side approaches
among European countries following the availability of generic
losartan. Only Western European countries and regions were
chosen as typically losartan was available as a generic much ear-
lier among Central and Eastern European countries; alternatively
only generic losartan was reimbursed and not single-sourced
ARBs (Voncina et al., 2011; Kalaba et al., 2012; Markovic-Pekovic
et al., 2012). The objective being to provide guidance on poten-
tial future approaches that the authorities could consider as they
seek to introduce additional measures to further enhance their
prescribing efficiency.
METHODOLOGY
The utilization of the different ARBs was calculated in terms of
defined daily doses (DDDs), with 2011 DDDs used in line with
International guidance (Ronning et al., 2000; Vlahovic-Palcevski
et al., 2010). DDDs are recognized as the international standard
to assess utilization patterns within and between countries
(WHO, 2003; Bennie et al., 2013). Only administrative databases
were used to assess utilization patterns. Details of these are
included in Box 1.
Losartan utilization was subsequently converted into a per-
centage of total ARB utilization (DDD basis) before and after the
availability of generic losartan (time zero) to enable meaningful
comparisons between the various European countries factoring
in differences in population sizes, time when generic losar-
tan became available (Table 1) and the database characteristics
between the countries (Box 1). The xtmixed command in Stata
versions 12/13 (StataCorp, College Station, Texas, USA) was used
to fit a linear random coefficient model with country specific
intercepts and slopes. The model included a change in the slope at
the time of introducing generic losartan in each country. Data on
the number of monthly reimbursed prescriptions for all patients
within each country’s health service prescribed a minimum of
one ARB (C09CA01 to 09) (Bucsics et al., 2012; Godman et al.,
2013a; Simoens et al., 2013; WHO Collaborating Centre for Drug
Statistics Methodology, 2013) at least 7 months before the avail-
ability of generic losartan in each country until at least 13 months
after was used in the analysis.
Separate analyses were undertaken in Austria, Belgium,
Denmark, Scotland and Sweden to assess whether the changes in
losartan utilization patterns post generics were significant or not
(Bucsics et al., 2012; Bennie et al., 2013; Godman et al., 2013a;
Hesse et al., 2013; Simoens et al., 2013). These were retrospec-
tive segmented regression analyses of an interrupted time series
design following the availability of generic losartan (Wagner et al.,
2002). In three of the countries, serial autocorrelations of losartan
prescription items dispensed were assessed with an ARIMAmodel
using a Box-Jenkins-Tiao strategy (McDowall et al., 1980; Bennie
et al., 2013; Godman et al., 2013a; Simoens et al., 2013), with
common segmented regression models used to fit a least-squares
regression line to each segment (Ross-Degnan et al., 1993). The
Durbin-Watson statistic was calculated in each country to test for
a serial autocorrelation of the error terms in the regression mod-
els to see whether significance was reached (P < 0.05) (Durbin,
1951; Brennan and Croft, 1994). In Austria, regression analyses
were undertaken using the “R Development Core Team”method-
ology to ascertain whether the change in losartan utilization post
generics was significant (Bucsics et al., 2012; R Development
Core Team, 2012). In the linear regression analysis in Denmark,
dummy variables were added to allow a change in intercept and in
slope in April 2010, when generic losartan was reimbursed, to test
for significance (Wagner et al., 2002; Hesse et al., 2013). Further
details can be found in the country specific publications.
A separate analysis was also undertaken in one English
primary care organization, NHS Bury, using a similar method-
ology to Belgium, Scotland and Sweden (Martin et al., 2014).
However in this case, the unit of measurement was prescription
items dispensed rather than DDDs as this is the typical metric
used to assess and compare utilization patterns in England
between different primary care groups (Martin et al., 2014). The
rationale for including this regional primary care organization
was that initially there were no specific demand-side measures
introduced following the availability of generic losartan; however,
multifaceted measures were introduced 7 months later including
therapeutic switching to help realize considerable savings (Martin
et al., 2014). Consequently this provides an additional exemplar
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Box 1 | Details of administrative databases use in the study and the date when generic losartan first reimbursed/included in the
drug tariff (Coma et al., 2009; Bucsics et al., 2012; Cahir et al., 2012; Bennie et al., 2013; Godman et al., 2013a; Hesse et al., 2013;
Simoens et al., 2013).
• Austria: Internal data warehouse of the HVB (Hauptverband der Österreichischen Sozialversicherungsträger)—BIG—coupled with
Cube HMSTAT, based on the “maschinelle Heilmittelabrechnung,” which covers approximately 98% of the Austrian population. Generic
losartan was reimbursed from October 2008.
• Belgium: Pharmanet—a database of reimbursed medicines dispensed in ambulatory care in Belgium. This database is maintained by
the National Institute for Health and Disability Insurance and covers the whole Belgian population. Generic losartan was reimbursed
from July 2010.
• Denmark: Danish Prescription Registry covering the entire Danish population. Generic losartan was reimbursed from April 2010.
• Ireland: The National Shared Services Primary Care Reimbursement Service of the Health Service Executive in Ireland (HSE-PCRS)
pharmacy claims database. This database provides details on monthly dispensed medications for each individual within the General
Medical Services (GMS) population. The GMS population covers approximately 30% of the population of Ireland with higher morbid-
ity than the general population—reflected in consuming approximately 65% of total pharmaceutical expenditure in Ireland. Generic
losartan was reimbursed in Ireland from March 2010.
• Scotland: NHS National Services Scotland Corporate Warehouse covering the entire population in Scotland. Generic losartan was
reimbursed (in the Drug Tariff) from July 2010.
• Spain (Catalonia): DMART (Catalan Health Service) database covering all patients in the public system in Catalonia. Generic losartan
was reimbursed from July 2006.
• Sweden: National Swedish Pharmacy Register covering the entire Swedish population. Generic losartan was reimbursed from March
2010.
case history of a regional health authority changing its policies
over time.
The percentage of losartan dispensed as generics vs. the orig-
inator was also calculated in all the European countries and
regions studied apart from Belgium to ascertain whether there
were any problems with generic losartan in clinical practice.
Fixed dose ARB combinations (FDCs) were not included in this
research as FDC utilization can be as low as 2% of total renin-
angiotensin inhibitor drug utilization in some countries (Voncina
et al., 2011; Bennie et al., 2013). There is also continuing contro-
versy surrounding the patient benefits of FDCs vs. titrating single
agents separately, especially if FDCs have higher drug acquisition
costs than the combination of each agent separately (Regional
Drugs and Therapeutics Centre (NHS), 2008; Voncina et al., 2011;
Kalaba et al., 2012).
We also calculated the percentage reduction in reimbursed
expenditure/ DDD for generic losartan vs. pre-patent loss orig-
inator prices over time as well as the influence of generic losartan
on subsequent ARB expenditure in separate analyses in a number
of countries. As a result, compare the influence of the different
policies on overall ARB prescribing efficiency with all ARBs seen
as essentially similar at appropriate dose titration (Heran et al.,
2008; Moon et al., 2010; Svanstrom et al., 2012).
The European countries and regions chosen for the study pro-
vided a range of geographical locations, different population sizes,
different approaches to the financing of health care, i.e., taxa-
tion or health insurance based, as well as different approaches
to enhancing the utilization of generics vs. originators and their
pricing (Godman et al., 2009, 2014; Abuelkhair et al., 2012;
Simoens, 2012; Vogler, 2012). Policies to encourage the pre-
scribing of generics vs. originators included prescribing targets,
e.g., Belgium, financial incentives either for physicians, patients,
or both, e.g., Austria, Belgium and Spain, encouraging volun-
tary International non-proprietary name (INN) prescribing, e.g.,
UK, and compulsory generic substitution, e.g., Sweden (Godman
et al., 2009, 2013c; Simoens, 2012; Simoens et al., 2013). Pricing
policies for generics included prescriptive pricing policies as well
as market forces encouraging their prescribing and dispensing
(Godman et al., 2012a, 2013c; Vogler, 2012). This methodol-
ogy is in line with recommended guidance for undertaking cross
national comparisons (Cacace et al., 2013).
The demand-side measures were collated under the
4Es—Education, engineering, economics, and enforcement
(Wettermark et al., 2009). These include (Godman et al., 2009,
2014; Wettermark et al., 2009, 2010; Garuoliene et al., 2011;
Gustafsson et al., 2011; Voncina et al., 2011; Markovic-Pekovic
et al., 2012):
• Education: Activities range from printed guide-
lines to more intensive strategies including academic
detailing and benchmarking physician prescribing
habits.
• Engineering: Refers to organizational or managerial inter-
ventions, e.g., prescribing targets and therapeutic switching
initiatives.
• Economics: includes financial incentives for physicians,
patients or pharmacists.
• Enforcement: includes regulations by law such as prescrib-
ing restrictions for ARBs in Austria, the Republic of Srpska
and Sweden as well as compulsory generic substitution or
compulsory INN prescribing.
A narrative review of health policies was undertaken in each
country and region following the availability of generic losartan
by one of the co-authors (Brian Godman). This was subsequently
checked with each co-author, in line with previous cross-national
studies (Godman et al., 2010a; Voncina et al., 2011).
RESULTS
The various European countries and regions approached the
opportunity of generic losartan differently (Table 1). These poli-
cies were in addition to general policies to enhance the prescribing
of generics which, as mentioned, included financial incentives for
physicians and patients, prescribing targets, compulsory generic
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Table 1 | Details of specific policies initiated among European countries following the availability of generic losartan.
Country Start of reimbursement
for generic losartan
Activities
Austria October 2008 Economics and Enforcement:
• Prescribing restrictions removed for losartan but not the other ARBs—ambulatory care
physicians still required to document the rationale for prescribing a patented (single-sourced)
ARB vs. an ACEI. The documents are subject to review by the health insurers
• Potential sanctions for abuse include physicians paying back to the Austrian Health Insurers an
estimate of the increased drug expenditure if any abuse of the reimbursement restrictions is
subsequently proven
Belgium July 2010 Economics and Enforcement
• Status of losartan changed from a “chapter IV” medicine to a “chapter I” medicine; however,
patented (single-sourced) ARBs remained chapter IV
• A chapter IV medicine can only be prescribed subject to prior approval—otherwise a 100%
co-payment. A chapter I medicine can be prescribed without restrictions
Denmark April 2010 Enforcement
• Delisting of all other ARBs than losartan from the reimbursed list
• Patients could still be prescribed another ARB and have this reimbursed. However, the
prescribing physician has to justify the rationale to the authorities and have the explanation
accepted before other ARBs can be reimbursed. Otherwise patients are subject to 100%
co-payment
Ireland March 2010 No specific activities were undertaken to influence the prescribing of losartan vs. single-sourced ARBs
Scotland July 2010 (Drug Tariff) No specific activities were undertaken to encourage the preferential prescribing of losartan vs.
patented (single-sourced) ARBs in view of other identified priorities by NHS Scotland as well as the
imminent launch of generics of other ARBs including candesartan, irbesartan, and valsartan
Ongoing multiple measures generally (Education, engineering, and economics) to encourage the
prescribing of generic ACEIs vs. ARBs
Spain (Catalonia) July 2006 No specific activities encouraging the preferential prescribing of losartan apart from highlighting
standard costs/DDD for ACEIs and ARBs in physician contracts
Sweden March 2010 Education, engineering, economics, and enforcement
• Education—County (Region) Drug and Therapeutics Committees encouraging the prescribing of
generic losartan; changes in county prescribing guidance, guidelines, and formularies to
recommend losartan first line for the management of hypertension or heart failure when an ARB
is indicated; academic detailing endorsing losartan as the ARB of choice; monitoring prescribing
habits against agreed guidance and feeding back the findings
• Engineering—Prescribing targets, e.g., % losartan as a % of all ARBs (DDD based); therapeutic
switching programmes were also initiated by some Counties (regions) to change patients on
single-sourced ARBs to losartan
• Economics—Budget devolution combined with positive or negative financial rewards to
physicians to encourage them to stay within budget; revision of physician or practice based
financial incentives to now include the prescribing of losartan vs. single-sourced ARBs
• Enforcement—From May 2011, prescribing restrictions were lifted for losartan but not the other
ARBs. In addition, originator losartan was removed from the reimbursement list
substitution and high voluntary INN prescribing (Godman et al.,
2008, 2009; Coma et al., 2009; Bennie et al., 2013; Simoens et al.,
2013).
This resulted in substantial differences in the subsequent uti-
lization of losartan vs. other ARBs (Figure 1). By changing the
reimbursement status of patented (single-sourced) ARBs, e.g.,
Denmark, the utilization of losartan rose to over 90% of all ARBs
(DDD basis) by the end of the study period.
There was an average increase in the utilization of losar-
tan of 0.82% units per month among the various European
countries and regions after the introduction of generic
losartan (month 0), with a large variability among them
(Figure 1). The standard deviation (SD) was 1.33% per month
(Table 2).
Separate country analyses showed a significant difference in
the utilization of losartan post generics in Austria, Belgium,
Denmark, and Sweden but not Scotland (further details can be
found in the country specific publications: Bucsics et al., 2012;
Bennie et al., 2013; Godman et al., 2013a; Hesse et al., 2013;
Simoens et al., 2013).
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FIGURE 1 | Percentage utilization of losartan vs. all single ARBs (DDD basis) before and after the availability of generic losartan (Time 0) on a
monthly basis.
Some countries instigated few or no specific demand-side
measures to stimulate the preferential prescribing of losartan
following generic availability. These were Ireland, Scotland, and
Spain (Catalonia) (Table 1). This resulted in no change or even
a fall in losartan use in Ireland as well as initially in Scotland
(Figure 2). There was appreciable consistency between these three
countries (Table 2), i.e., excluding the European countries that
had instigated multiple demand-side measures from the analysis
(Denmark, Sweden, Belgium, and Austria) resulted in very lim-
ited change in the post-generic utilization slopes with an average
of 0.10% and an SD of 0.08% (Table 2).
Losartan utilization increased significantly in NHS Bury fol-
lowing the instigation of multiple demand-side measures, which
were similar to Sweden (Table 1). These principally centered on
the therapeutic switching of patients with hypertension from
single-sourced ARBs to losartan (Martin et al., 2014). These
multiple demand-side measures were introduced seven months
after the availability of generic losartan. Prior to that, there was
no change in the utilization of losartan post generic availabil-
ity (Time Zero—Table 3) with no specific demand-side measures
encouraging the preferential prescribing of losartan vs. single-
sourced ARBs. Following the multiple demand-side measures
(DM0) introduced in month eight after generic losartan, the uti-
lization of losartan significantly increased from 26% of all single
ARB items dispensed to 65% by the end of the study period
(Table 3).
Generic losartan accounted for up to 97–99% of total losartan
(DDD basis) by the end of the study in Sweden and Scotland
Table 2 | Average change in regression slopes after the introduction
of generic losartan and corresponding standard deviations over
different groupings of the included countries.
Countries Change in slope % Standard deviation
units per month of the change in
(95% CI) slope SD (95% CI)
All 0.82 (−0.17 to 1.82) 1.33 (0.78 to 2.26)
Excluding Denmark 0.30 (0.04 to 0.56) 0.32 (0.18 to 0.57)
Excluding Denmark and
Sweden
0.22 (0.02 to 0.43) 0.23 (0.12 to 0.43)
Excluding Denmark, Sweden,
Austria, Belgium
0.10 (0.01 to 0.20) 0.08 (0.03 to 0.19)
respectively. This was due to compulsory generic substitution
in Sweden (Godman et al., 2009, 2013a) and high voluntary
INN prescribing in Scotland (Bennie et al., 2013; Godman et al.,
2013c). High INN prescribing rates were already seen in Scotland
before generic losartan became available. There was lower utiliza-
tion of generic losartan as a percentage of total losartan utilization
(DDD basis) in Spain, Austria and Ireland. This was 80% in Spain
(26% after 1 year), 46% in Austria and 24% in Ireland by the end
of the study in each country.
The price of generic losartan (expenditure/ DDD) also var-
ied considerably among the different European countries and
regions. In Sweden, Denmark (total losartan), Scotland, and
Austria, the price of generic losartan was 10, 12, 12, and 17%
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FIGURE 2 | Percentage utilization losartan vs. all single ARBs (DDD based) among the European countries with no multiple demand-side measures
to preferentially enhance the prescribing of losartan (Table 1) before and after the availability of generic losartan (Time 0) on a monthly basis.
respectively of pre-patent loss prices by the end of the study. Prices
for generic losartan were higher in Spain (Catalonia), Belgium
(total losartan including both generic and originator losartan)
and Ireland at 32, 54, and 56% respectively of pre-patent loss
prices by the end of the study.
The combination of supply- and demand-side measures in
Denmark resulted in a 77% reduction in overall ARB expendi-
ture by the end of the study despite a 16% increase in utilization.
Drug acquisition cost savings were estimated at over 290 million
Danish Kroner (C40million) per annum. In Sweden, total expen-
diture on single ARBs fell by 26% by the end of the study despite
a 16% increase in utilization and in Belgium ARB expenditure
fell by 15% by the end of the study despite a 1% increase in uti-
lization. NHS Bury realized annual net savings of GB£290,000
(C348,000) for a population of 186,000 following the instigation
of its multiple demand-side measures. This was eight times the
cost of implementing their multifaceted approach. In Scotland,
drug acquisition cost savings from low cost generics were esti-
mated at GB£8 million (C9.6 million) per annum from the
prescribing of generic vs. single-sourced losartan. These savings
are growing in Scotland as more ARBs lose their patents.
DISCUSSION
Generic losartan created an opportunity for health authorities
across Europe to realize considerable savings without compromis-
ing care. This is because separate studies, including therapeutic
switching programmes, have shown that patient outcomes should
not be compromised with such measures (Usher-Smith et al.,
2008; Moon et al., 2010; Martin et al., 2014). A number of similar
opportunities are pending with other patent expiries to provide
future opportunities to health authorities (Jack, 2008; Godman
et al., 2013d). The approach of some countries, e.g., Denmark,
shows that these savings can be fully realized for pertinent
classes. Aggressive changes in the reimbursement status of the
single-sourced ARBs resulted in the prescribing of generic ARBs,
i.e., losartan, in over 90% of cases. Without specific demand-side
measures preferentially encouraging the prescribing of losartan,
its prescribing remained stable or actually fell following generics
(Figures 1, 2, Table 2).
Replicating the activities in Denmark throughout Europe
would result in considerable savings with generic losartan priced
at one 10th of the price of single-sourced products as seen in
Scotland (Bennie et al., 2013). In other circumstances, such dif-
ferences in the use of taxpayers’ monies would result in serious
public debate. Here, it is more likely that the influence of phar-
maceutical companies promoting their single-sourced ARBs, the
potential dissociation of the prescriber from the budget holder,
other health authority priorities or a combination of these,
resulted in the appreciable differences in physician prescribing
behavior post generic losartan (Figure 1). It is perhaps sufficient
to say that if all European countries mirrored the activities in
Denmark (Table 1), billions of euros could have been redirected
without compromising care with all ARBs seen as therapeutically
similar at appropriate doses. Multiple demand-side measures in
NHS Bury and Sweden, including therapeutic switching, also pro-
duced considerable savings even when factoring in the cost of
implementation including physician time from switching patients
from single-sourced ARBs to losartan (Godman et al., 2013a;
Martin et al., 2014). These two countries and regions provide
examples where it is difficult for health authorities to delist
single-sourced products in a class from the reimbursement list.
Some interventions were less effective than others. Lifting
prescribing restrictions for losartan but not the other ARBs in
Austria and Belgium (Table 1) significantly enhanced its use
(Figure 1) (Bucsics et al., 2012; Simoens et al., 2013). However,
the resultant change in its utilization was lower than the changes
seen in either Denmark, Sweden, or NHS Bury post generic
losartan (Figure 1, Table 3). Having said this, Figures 1, 2 and
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Tables 1, 2 demonstrate again that multiple demand-side mea-
sures are needed to change physician prescribing habits (Austria,
Belgium, Denmark and Sweden vs. Ireland, Scotland, and Spain
[Catalonia]). This has previously been seen with the proton pump
inhibitors and statins following the availability of generic omepra-
zole and simvastatin respectively (Godman et al., 2010a,b), as
well as with demand-side measures to enhance the prescribing
of generic ACEIs vs. single-sourced ARBs (Voncina et al., 2011;
Godman et al., 2013c). This has also been seen in other situations
(Bero et al., 1998; Barton, 2001).
The findings in Scotland and initially NHS Bury also suggest
there is no “spill over” learning from one class to another to effect
changes in physician prescribing habits even if the classes are
closely related. Multiple demand-side measures (education, engi-
neering’, and economics) had appreciably limited the utilization
of single-sourced ARBs vs. generic ACEIs in Scotland compared
with countries with few demand-side measures (Voncina et al.,
2011; Godman et al., 2013c). However, these learnings were not
carried through into the preferential prescribing of losartan vs.
single-sourced ARBs once it became available (Bennie et al., 2013;
Martin et al., 2014). This changed in NHS Bury once multiple
demand-side measures were introduced to significantly enhance
the prescribing of losartan vs. single-sourced ARBs (Martin et al.,
2014). One mitigating reason for the lack of a “spill over” effect
in Scotland, and initially in NHS Bury, could be that the com-
plexity of the message is enhanced, i.e., health authorities going
from advocating ACEIs first line vs. ARBs to advocating ACEIs
and low cost ARB first line vs. single-sourced ARBs (Bennie et al.,
2013).
There appeared to be no problems with generic losartan in
clinical practice as it accounted for up to 97–99% of total losar-
tan (DDD basis) by the end of the study period in Sweden and
Scotland respectively (Bennie et al., 2013; Godman et al., 2013a).
However, we cannot say this with certainty as we did not have
access to patient data. The high voluntary INN prescribing rates
with losartan in Scotland mirror those seen with other products
and classes (Godman et al., 2013c). This starts with educating
students in medical school (Voncina et al., 2011; Godman et al.,
2013c), and provides guidance to countries where the dispens-
ing of different branded generics without adequate explanations
can cause confusion if patients do not receive adequate infor-
mation about their medicines (Godman et al., 2009; Olsson and
Kalvemark Sporrong, 2012). This can lead to either duplication of
medicines; alternatively, patients not taking their prescribed treat-
ments as directed. Consequently, not gaining the most benefit
from themedicines prescribed (Olsson et al., 2014). These scenar-
ios are exacerbated if pharmacists lack training on how to handle
concerns with substitution and/ or do not receive adequate pay-
ment for providing relevant information to patients potentially
limiting their time with them (Olsson and Kalvemark Sporrong,
2012; Martin et al., 2014). INN prescribing, apart from a lim-
ited number of well-known situations, is one way to address this,
which has worked well in the UK (McGinn et al., 2010; Godman
et al., 2013c).
There were also considerable differences in prices of generic
losartan among the different countries and regions. This reflects
differences in their policies to enhance the utilization of generics
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as well as the different pricing policies for generics. The low prices
for generic losartan in Scotland, which is similar to those for other
generics, follows reforms in the UK to enhance transparency in
the cost of producing generics as well as the discounts offered by
manufacturers to wholesalers and pharmacists to preferentially
dispense their generic (Voncina et al., 2011; Bennie et al., 2012,
2013; Godman et al., 2013c). The price reduction in Sweden,
which is also similar to other generics, is a result of introducing
compulsory generic substitution with the lowest priced molecule
(Andersson et al., 2005; Godman et al., 2009, 2013a). Generic
prices are falling further in Sweden with the recent introduc-
tion of monthly auctions, with the manufacturer winning the
auction guaranteed a considerable proportion of dispensed gener-
ics the following month (Godman et al., 2012a,b). The modest
price reduction for generic losartan in Belgium reflects the cur-
rent situation where generic companies only have to lower their
prices to the reference price level to be reimbursed. This was only
16% vs. pre-patent loss prices until 2002, 20% until 2003, 26%
until 2005, and currently 31% (Godman et al., 2013e; Simoens
et al., 2013). The relatively high price for generic losartan in
Ireland reflects limited measures to date to reduce generic prices,
although this is now changing (Godman et al., 2010a; Cahir et al.,
2012). Consequently, measures to increase the attractiveness of
the generic market, as well as enhance the transparency in their
pricing as seen in Sweden and the UK, provide guidance to coun-
tries seeking ways to achieve further savings from the availability
of generics.
We appreciate that we have not measured patient outcomes in
any of the European countries and regions following the various
initiatives apart from NHS Bury. However as stated, surveillance
and other studies have shown no compromise on patient out-
comes following measures to increase the prescribing of low cost
ARBs (Usher-Smith et al., 2008; Moon et al., 2010; Svanstrom
et al., 2012; Martin et al., 2014).
CONCLUSION
The loss of market exclusivity for medicines can create con-
siderable opportunities for European health authorities to save
resources to help fund increased drug volumes and new pre-
mium priced drugs (Godman et al., 2014). This losartan
case study shows that multiple demand-side measures can be
extremely effective with influencing subsequent physician pre-
scribing. Without these, prescribing rates for multiple sourced
products in a class can actually fall. However, some inter-
ventions are less effective than others. If all European coun-
tries followed the example of Denmark, NHS Bury in later
years, or Sweden, considerable resources could have been saved.
Having said this, there does appear at times to be a disconnect
between the physician prescriber and the payer of medicines,
creating a dissociation of responsibility which is reducing cost-
effective prescribing. If we are to maintain the European ideals
of comprehensive and equitable healthcare, we must urgently
address this.
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